Berlin - Delayed Quote EUR

Editas Medicine Inc (8EM.BE)

1.4920

+0.0395

+(2.72%)

At close: June 3 at 8:03:57 AM GMT+2

1 Stock Down 97% That Could Double, According to Wall Street

Editas Medicine (NASDAQ: EDIT), a gene-editing-focused clinical-stage biotech, is firmly in the speculative camp, which is why its shares are down by 97% since early 2021. Developing and marketing gene-editing therapies is challenging, as Editas Medicine knows well. Here is the problem: Ex vivo gene-editing therapies are complex to administer.

Motley Fool 9 days ago

EDIT
A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.

Pharma Voice 19 days ago

EDIT
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from

GlobeNewswire 20 days ago

EDIT
Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Editas Medicine ( NASDAQ:EDIT ) First Quarter 2025 Results Key Financial Results Revenue: US$4.66m (up 310% from 1Q...

Simply Wall St. 20 days ago

EDIT
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary

GlobeNewswire 20 days ago

EDIT
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

Here is how Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Zacks 21 days ago

EDIT

ABUS
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y

EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.

Zacks 21 days ago

EDIT
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared in vivo proof of concept data supporting the development of a potentially first-in-class treatment for an undisclosed liver target in a poster presentation at the 28th Annual Meeting of the American Society of Gene

GlobeNewswire 21 days ago

EDIT
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 15.69% and 385.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 22 days ago

EDIT

LCTX
Editas: Q1 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Editas Medicine Inc. EDIT) on Monday reported a loss of $76.1 million in its first quarter.

Associated Press Finance 22 days ago

EDIT
Editas Medicine Announces First Quarter 2025 Results and Business Updates

Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to upregulate expression of a target liver protein to meaningfully reduce a common disease-associated biomarker at ASGCT this week and TIDES next week Remains on track to declare two in vivo gene editing development candi

GlobeNewswire 22 days ago

EDIT
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and Appeal Board’s (PTABs) previous decision and remanded it back to the PTAB for further review in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of

GlobeNewswire 22 days ago

EDIT
Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?

Editas (EDIT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 22 days ago

EDIT
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will particip

GlobeNewswire 29 days ago

EDIT
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines.

GlobeNewswire last month

EDIT
Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year

Key Insights Given the large stake in the stock by institutions, Editas Medicine's stock price might be vulnerable to...

Simply Wall St. last month

EDIT
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

EDIT
AstraZeneca deepens China investment; Editas loses CFO to Dyne

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

BioPharma Dive 2 months ago

AZN

EDIT

PFE
Editas Medicine Announces Chief Financial Officer Transition

Amy Parsion Senior Vice President of Finance Amy Parison Appointed CFO Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy

GlobeNewswire 2 months ago

EDIT
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 2 months ago

EDIT

Performance Overview

Return	8EM.BE	S&P 500 (^GSPC)
YTD	+28.68%	+1.51%
1-Year	-67.43%	+13.00%
3-Year	-85.99%	+45.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Editas Medicine Inc (8EM.BE)

1 Stock Down 97% That Could Double, According to Wall Street

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Editas: Q1 Earnings Snapshot

Editas Medicine Announces First Quarter 2025 Results and Business Updates

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

AstraZeneca deepens China investment; Editas loses CFO to Dyne

Editas Medicine Announces Chief Financial Officer Transition

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

Performance Overview